Related Experiment Video

Updated: Jul 18, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Carbohydrate antigens: synthesis aspects and immunological applications in cancer

Teresa Freire1, Sylvie Bay, Sophie Vichier-Guerre

  • 1CNRS, URA2128, Unité de Chimie Organique, Paris, France. tfreire@pasteur.fr

Mini Reviews in Medicinal Chemistry
|December 16, 2006
PubMed

Insights

Tumor Associated Carbohydrate Antigens (TACAs) are vital for cancer detection and immunotherapy. This review covers the production of TACA-based vaccines and their effectiveness in preclinical and clinical cancer studies.

Area of Science:

  • Oncology
  • Immunology
  • Carbohydrate Chemistry

Background:

  • Tumor Associated Carbohydrate Antigens (TACAs) are crucial biomarkers in cancer diagnostics.
  • TACAs are also promising targets for developing novel anticancer immunotherapies.

Purpose of the Study:

  • To review the methodologies for producing glycopeptide-based vaccines targeting TACAs.
  • To summarize the findings from preclinical and clinical investigations of these vaccines in cancer patients.

Main Methods:

  • Glycopeptide synthesis and vaccine formulation.
  • Preclinical cancer models for efficacy assessment.
  • Clinical trial data analysis for safety and immunogenicity.

Main Results:

  • Successful production of various glycopeptide-based vaccines.
  • Demonstrated preclinical efficacy in reducing tumor burden.
  • Promising safety and immunogenicity profiles observed in early-phase clinical trials.

Conclusions:

  • Glycopeptide-based vaccines targeting TACAs represent a viable strategy for cancer immunotherapy.
  • Further clinical development is warranted to establish their therapeutic role in cancer treatment.

More Related Videos

Hierarchical and Programmable One-Pot Oligosaccharide Synthesis09:56

Hierarchical and Programmable One-Pot Oligosaccharide Synthesis

Published on: September 6, 2019

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens09:53

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

Related Concept Videos

Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Antigen Processing Pathways01:31

Antigen Processing Pathways

MHC molecules are key players in the immune response, enabling T cells to recognize and respond to specific antigens. They are present on the surface of all nucleated cells in the body and are instrumental in presenting antigens to T cells and activating them. T cells recognize the MHC-antigen complex and initiate an immune response. MHC class I and MHC class II are two main types of MHC molecules, each associated with a distinct antigen processing pathway.
MHC Class I: Presenting Endogenous...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...